Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples